SFTPB in serum extracellular vesicles as a biomarker of progressive pulmonary fibrosis
Authors:
- Takatoshi EnomotoTETakatoshi Enomoto
- Yuya ShiraiYSYuya Shirai
- Yoshito TakedaYTYoshito Takeda
- Ryuya EdahiroRERyuya Edahiro
- Shigeyuki ShichinoSSShigeyuki Shichino
- Mana NakayamaMNMana Nakayama
- Miho Takahashi-ItohMTMiho Takahashi-Itoh
- Yoshimi NodaYNYoshimi Noda
- Yuichi AdachiYAYuichi Adachi
- Takahiro KawasakiTKTakahiro Kawasaki
- Taro KobaTKTaro Koba
- Yu FutamiYFYu Futami
Open Access
- 7 May 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (11)
Abstract
Progressive pulmonary fibrosis (PPF), defined as the worsening of various interstitial lung diseases (ILDs), currently lacks useful biomarkers. To identify novel biomarkers for early detection of patients at risk of PPF, we performed a proteomic analysis of serum extracellular vesicles (EVs). Notably, the identified candidate biomarkers were enriched for lung-derived proteins participating in fibrosis-related pathways. Among them, pulmonary surfactant-associated protein B (SFTPB) in serum EVs could predict ILD progression better than the known biomarkers, serum KL-6 and SP-D, and it was identified as an independent prognostic factor from ILD-gender-age-physiology index. Subsequently, the utility of SFTPB for predicting ILD progression was evaluated further in 2 cohorts using serum EVs and serum, respectively, suggesting that SFTPB in serum EVs but not in serum was helpful. Among SFTPB forms, pro-SFTPB levels were increased in both serum EVs and lungs of patients with PPF compared with those of the control. Consistently, in a mouse model, the levels of pro-SFTPB, primarily originating from alveolar epithelial type 2 cells, were increased similarly in serum EVs and lungs, reflecting pro-fibrotic changes in the lungs, as supported by single-cell RNA sequencing. SFTPB, especially its pro-form, in serum EVs could serve as a biomarker for predicting ILD progression.Keywords
Funding Information
- the Ministry of Health, Labor, and Welfare (JPMH20AC5001,19AC5001)
- the Japan Society for the Promotion of Science (JSPS) KAKENHI (22H05064,JP18H05282,JP19K08650,22K08283)
This publication has 47 references indexed in Scilit:
- Serum Proteomics Identifies Biomarkers Associated With the Pathogenesis of Idiopathic Pulmonary FibrosisMolecular & Cellular Proteomics, 2023
- Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinomaJournal of Hepatology, 2023
- Investigating serum extracellular vesicles in Cystic FibrosisJournal of Cystic Fibrosis, 2023
- Quantitative performance of digital ELISA for the highly sensitive quantification of viral proteins and influenza virusAnalytical and Bioanalytical Chemistry, 2023
- Comprehensive proteomic profiling of plasma and serum phosphatidylserine-positive extracellular vesicles reveals tissue-specific proteinsiScience, 2022
- Nintedanib: A Review in Fibrotic Interstitial Lung DiseasesDrugs, 2021
- Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive PhenotypeChest, 2020
- Therapeutic Approach to Adult Fibrotic Lung DiseasesChest, 2016
- Activation of AMP-Activated Protein Kinase Prevents TGF-β1–Induced Epithelial-Mesenchymal Transition and Myofibroblast ActivationThe American Journal of Pathology, 2015
- Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosisEuropean Respiratory Journal, 1999